Smokeless tobacco;Tabac non fumé

Revue des Maladies Respiratoires

Volumn 28, Issue 8, 2011, Pages 978-994

  Underner, M ^a   Perriot, J ^b  

^a Service de Pneumologie   (France)

^b Dispensaire Émile Roux ^*  (France)

Author keywords

Cancer; Cardiovascular diseases; Nicotine dependence; Smokeless tobacco; Snuff

Indexed keywords

AMFEBUTAMONE; NICOTINE;

BETEL NUT; BRAIN ISCHEMIA; CANCER RISK; ERYTHROPLASIA; HEART INFARCTION; LEUKOPLAKIA; MOUTH DISEASE; MOUTH LESION; NICOTINE REPLACEMENT THERAPY; PANCREAS CANCER; PERIODONTAL DISEASE; PREMATURE LABOR; REVIEW; SMOKELESS TOBACCO; STILLBIRTH; WITHDRAWAL SYNDROME;

CARDIOVASCULAR DISEASES; FEMALE; HUMANS; INFANT, NEWBORN; MOUTH DISEASES; NEOPLASMS; PREGNANCY; PREGNANCY COMPLICATIONS; TOBACCO USE DISORDER; TOBACCO, SMOKELESS;

EID: 84155167139     PISSN: 07618425     EISSN: 17762588     Source Type: Journal    
DOI: 10.1016/j.rmr.2011.08.003     Document Type: Review

References (182)

1. Dautzenberg B. Le tabac à sucer, cette drôle d'idée que la Suède veut exporter. Info Respiration (Paris) n° 96, avril 2010.
2. Walsh PM, Epstein JB. The oral effects of smokeless tobacco. J Can Dent Assoc 2000;66:22-5.
3. Johnson N. Tobacco use and oral cancer: a global perspective. J Dent Educ 2001;65:328-39.
4. Gupta PC, Ray CS. Epidemiology of betel quid usage. Ann Acad Med Singapore 2004;33:31-6.
5. Walling AD. Smokless tobacco-health hazards from a good'ole habit. JR Coll Gen Pract 1986;36:466-7. (Pubitemid 17196851)
6. Joossens L. EC oral snuff ban and Sweden. Lancet 1992;340:57.
7. Gupta PC, Ray CS. Smokeless tobacco and health in India and South Asia. Respirology 2003;8:419-31. (Pubitemid 38009636)
8. Hu FB, Hedeker D, Flay BR, et al. The patterns and predictors of smokeless tobacco onset among urban public school teenagers. Am J Prev Med 1996;12:22-8. (Pubitemid 26077385)
9. Walsh MM, Hilton JF, Ernster VL, et al. Prevalence, patterns, and correlates of spit tobacco use in a college athlete population. Addict Behav 1994;19:411-27. (Pubitemid 24233175)
10. Cummings KM, Michalek AM, Carl W, et al. Use of smokeless tobacco in a group of professional baseball players. J Behav Med 1989;12:559-67. (Pubitemid 20167426)
11. Tomar SL, Hatsukami DK. Perceived risk of harm from cigarettes or smokeless tobacco among US high school seniors. Nicotine Tob Res 2007;9:1191-6. (Pubitemid 350066237)
12. Nilsson R. A qualitative and quantitative risk assessment of snuff dipping. Regul Toxicol Pharmacol 1998;28:1-16. (Pubitemid 28492173)
13. Ayo-Yusuf OA, Swart TJ, Pickworth WB. Nicotine delivery capabilities of smokeless tobacco products and implications for control of tobacco dependence in South Africa. Tob Control 2004;13:186-9. (Pubitemid 39452020)
14. Bourlaud I, Underner M, Perault MC, et al. Pharmacologie de la nicotine. Rev Mal Respir 1992;9:367-74.
15. Foulds J, Ramstrom L, Burke M, et al. Effect of smokeless tobacco (snus) on smoking and public health in Sweden. Tob Control 2003;12:349-59. (Pubitemid 39452035)
16. Hoffmann D, Djordjevic MV, Fan J, et al. Five leading US commercial brands of moist snuff in 1994: assessment of carcinogenic N-nitrosamines. J Natl Cancer Inst 1995;87:1862-9. (Pubitemid 3012656)
17. Fant RV, Henningfield JE, Nelson RA, et al. Pharmacokinetics and pharmacodynamics of moist snuff in humans. Tob Control 1999;8:387-92.
18. Gritz ER, Baer-Weiss V, Benowitz NL, et al. Plasma nicotine and cotinine concentrations in habitual smokeless tobacco users. Clin Pharmacol Ther 1981;30:201-9. (Pubitemid 11039358)
19. Holm H, Jarvis MJ, Russell MA, et al. Nicotine intake and dependence in Swedish snuff takers. Psychopharmacology (Berl) 1992;108:507-11.
20. Benowitz NL. Systemic absorption and effects of nicotine from smokeless tobacco. Adv Dent Res 1997;11:336-41.
21. Wennmalm A, Benthin G, Granström EF, et al. Relation between tobacco use and urinary excretion of thromboxane A2 and prostacyclin metabolites in young men. Circulation 1991;83:1698-704.
22. Bolinder G, Norén A, de Faire U, et al. Smokeless tobacco use and atherosclerosis: an ultrasonographic investigation of carotid intima media thickness in healthy middle-aged men. Atherosclerosis 1997;132:95-103. (Pubitemid 27306744)
23. Benowitz NL, Jacob 3rd P, Yu L. Daily use of smokeless tobacco: systemic effects. Ann Intern Med 1989;111:112-6. (Pubitemid 19180321)
24. Hoffmann D, Djordjevic MV. Chemical composition and carcinogenicity of smokeless tobacco. Adv Dent Res 1997;11:322-9.
25. Djordjevic MV, Brunnemann KD, Hoffmann D. The need for regulation of carcinogenic N-nitrosamines in oral snuff. Food Chem Toxicol 1993;31:497-501. (Pubitemid 23204032)
26. Murphy SE, Carmella SG, Idris AM, et al. Uptake and metabolism of carcinogenic levels of tobacco-specific nitrosamines by Sudanese snuff dippers. Cancer Epidemiol Biomarkers Prev 1994;3:423-8. (Pubitemid 24221452)
27. Kresty LA, Carmella SG, Borukhova A, et al. Metabolites of a tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), in the urine of smokeless tobacco users: relationship between urinary biomarkers and oral leukoplakia. Cancer Epidemiol Biomarkers Prev 1996;5: 521-5. (Pubitemid 26235018)
28. Osterdahl BG, Slorach SA. Volatile N-nitrosamines in snuff and chewing tobacco on the Swedish market. Food Chem Toxicol 1983;21:759-62. (Pubitemid 14216189)
29. Benowitz NL. Snuff, nicotine and cardiovascular disease: implications for tobacco control. J Am Coll Cardiol 1999;34:1791-3.
30. Hatsukami D, Anton D, Keenan R, et al. Smokeless tobacco abstinence effects and nicotine gum dose. Psychopharmacology (Berl) 1992;106:60-6.
31. Post A, Gilljam H, Rosendahl I, et al. Symptoms of nicotine dependence in a cohort of Swedish youths: a comparison between smokers, smokeless tobacco users and dual tobacco users. Addiction 2010;105:740-6.
32. Henley SJ, Thun MJ, Connell C, et al. Two large prospective studies of mortality among men who use snuff or chewing tobacco (United States). Cancer Causes Control 2005;16:347-58. (Pubitemid 40897827)
33. Kleinman DV, Swango PA, Pindborg JJ. Epidemiology of oral mucosal lesions in United States schoolchildren: 1986-87. Community Dent Oral Epidemiol 1994;22:243-53.
34. Greer Jr RO, Poulson TC. Oral tissue alterations associated with the use of smokeless tobacco by teenagers. Part I. Clinical findings. Oral Surg Oral Med Oral Pathol 1983;56:275-84. (Pubitemid 14234725)
35. Winn DM. Tobacco use and oral disease. J Dent Educ 2001;65:306-12.
36. Robertson PB,Walsh MM, Greene JC. Oral effects of smokeless tobacco use by professional baseball players. Adv Dent Res 1997;11:307-12.
37. Offenbacher S, Weathers DR. Effects of smokeless tobacco on the periodontal, mucosal and caries status of adolescent males. J Oral Pathol 1985;14:169-81.
38. Tomar SL, Winn DM. Chewing tobacco use and dental caries among US men. J Am Dent Assoc 1999;130:1601-10.
39. Mavropoulos A, Aars H, Brodin P. The involvement of nervous and some inflammatory response mechanisms in the acute snuff-induced gingival hyperaemia in humans. J Clin Periodontol 2002;29:855-64. (Pubitemid 41697803)
40. Poore TK, Johnson GK, Reinhardt RA, et al. The effects of smokeless tobacco on clinical parameters of inflammation and gingival crevicular fluid prostaglandin E2, interleukin-1 alpha, and interleukin-1 beta. J Periodontol 1995;66:177-83.
41. Amarasena N, Ekanayaka AN, Herath L, et al. Association between smoking, betel chewing and gingival bleeding in rural Sri Lanka. J Clin Periodontol 2003;30:403-8. (Pubitemid 38037097)
42. Robertson PB, Walsh M, Greene J, et al. Periodontal effects associated with the use of smokeless tobacco. J Periodontol 1990;61:438-43.
43. Modéer T, Lavstedt S, Ahlund C. Relation between tobacco consumption and oral health in Swedish schoolchildren. Acta Odontol Scand 1980;38:223-7. (Pubitemid 11228600)
44. Riley JL3rd, Tomar SL, Gilbert GH. Smoking and smokeless tobacco: increased risk for oral pain. J Pain 2004;5:218-25. (Pubitemid 38881116)
45. Underner M, Maes I, Urban T, et al. Effets du tabac sur la maladie parodontale. Rev Mal Respir 2009;26:1057-73.
46. Kassab MM, Cohen RE. The etiology and prevalence of gingival recession. J Am Dent Assoc 2003;134:220-5. (Pubitemid 38175570)
47. Hirsch JM, Johansson SL. Effect of long-term application of snuff on the oral mucosa: an experimental study in the rat. J Oral Pathol 1983;12:187-98. (Pubitemid 13059667)
48. Gao XP, Vishwanatha JK, Conlon JM, et al. Mechanisms of smokeless tobacco-induced oral mucosa inflammation: role of bradykinin. J Immunol 1996;157:4624-33. (Pubitemid 126449385)
49. Vishwanatha JK, Swinney R, Banerjee AG. Modulation of annexin I and cyclooxygenase-2 in smokeless tobaccoinduced inflammation and oral cancer. Mol Cell Biochem 2003;248:67-75. (Pubitemid 36833642)
50. Warnakulasuriya KA, Ralhan R. Clinical, pathological, cellular and molecular lesions caused by oral smokeless tobacco-a review. J Oral Pathol Med 2007;36:63-77. (Pubitemid 46089306)
51. Johnson GK, Poore TK, Payne JB, et al. Effect of smokeless tobacco extract on human gingival keratinocyte levels of prostaglandin E2 and interleukin-1. J Periodontol 1996;67:116-24. (Pubitemid 26080442)
52. Reichart PA, Phillipsen HP. Betel chewer's mucosa-a review. J Oral Pathol Med 1998;27:239-42.
53. Andersson G, Björnberg G, Curvall M. Oral mucosal changes and nicotine disposition in users of Swedish smokeless tobacco products: a comparative study. J Oral Pathol Med 1994;23:161-7. (Pubitemid 2082988)
54. Reichart PA, Schmidtberg W, Samaranayake LP, et al. Betel quid-associated oral lesions and oral Candida species in a female Cambodian cohort. J Oral Pathol Med 2002;31:468-72.
55. Ayo-Yusuf OA, Swart TJ, Ayo-Yusuf IJ. Prevalence and pattern of snuff dipping in a rural South African population. SADJ 2000;55:610-4.
56. Kaugars GE, Brandt RB, Chan W, et al. Evaluation of risk factors in smokeless tobacco-associated oral lesions. Oral Surg Oral Med Oral Pathol 1991;72:326-31.
57. Grady D, Ernster VL, Stillman L, et al. Smokeless tobacco use prevents aphthous stomatitis. Oral Surg Oral Med Oral Pathol 1992;74:463-5.
58. Hirsch JM, Heyden G, Thilander H. A clinical, histomorphological and histochemical study on snuff-induced lesions of varying severity. J Oral Pathol 1982;11:387-98. (Pubitemid 12035511)
59. Jungell P, Malmström M. Snuff-induced lesions in Finnish recruits. Scand J Dent Res 1985;93:442-7. (Pubitemid 15236181)
60. Daniels TE, Chou L, Greenspan JS, et al. Reduction of Langerhans cells in smokeless tobacco-associated oral mucosal lesions. J Oral Pathol Med 1992;21:100-4.
61. Park NH, Herbosa EG, Sapp JP. Effect of tar condensate from smoking tobacco and water-extract of snuff on the oral mucosa of mice with latent herpes simplex virus. Arch Oral Biol 1987;32:47-53.
62. Hirsch JM, Johansson SL, Thilander H, et al. Effect of longterm application of snuff and herpes simplex virus 1 on rat oral mucosa. Possible association with development of oral cancer. IARC Sci Publ 1984;57:829-36.
63. Park NH, Sapp JP, Herbosa EG. Oral cancer induced in hamsters with herpes simplex infection and simulated snuff dipping. Oral Surg Oral Med Oral Pathol 1986;62:164-8.
64. Hecht SS, Rivenson A, Braley J, et al. Induction of oral cavity tumors in F344 rats by tobacco-specific nitrosamines and snuff. Cancer Res 1986;46:4162-6. (Pubitemid 16075924)
65. Adhvaryu SG, Dave BJ, Trivedi AH. Cytogenetic surveillance of tobacco-areca nut (mava) chewers, including patients with oral cancers and premalignant conditions. Mutat Res 1991;261:41-9.
66. Sawhney M, Rohatgi N, Kaur J, et al. Expression of NFkappaB parallels COX-2 expression in oral precancer and cancer: association with smokeless tobacco. Int J Cancer 2007;120:2545-56. (Pubitemid 46651274)
67. Mishra R, Das BR. Cyclin D1 expression and its possible regulation in chewing tobacco mediated oral squamous cell carcinoma progression. Arch Oral Biol 2009;54:917-23.
68. Sharma C, Kaur J, Shishodia S, et al. Curcumin down regulates smokeless tobacco-induced NF-kappaB activation and COX-2 expression in human oral premalignant and cancer cells. Toxicology 2006;228:1-15. (Pubitemid 44548099)
69. Greer Jr RO, Meyers A, Said SM, et al. Is p16(INK4a) protein expression in oral ST lesions a reliable precancerous marker? Int J Oral Maxillofac Surg 2008;37:840-6.
70. Murrah VA, Gilchrist EP, Moyer MP. Attenuation of the natural course of herpes simplex virus infection in human oral epithelial cell cultures by smokeless tobacco extracts suggests the possibility of a synergistic mechanism for carcinogenesis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996;81:63-9. (Pubitemid 126812882)
71. Livingston GK, Reed RN, Olson BL, et al. Induction of nuclear aberrations by smokeless tobacco in epithelial cells of human oral mucosa. Environ Mol Mutagen 1990;15:136-44. (Pubitemid 20179117)
72. Proia NK, Paszkiewicz GM, Nasca MA, et al. Smoking and smokeless tobacco-associated human buccal cell mutations and their association with oral cancer-a review. Cancer Epidemiol Biomarkers Prev 2006;15:1061-77.
73. Ernster VL, Grady DG, Greene JC, et al. Smokeless tobacco use and health effects among baseball players. JAMA 1990;264:218-24. (Pubitemid 20212582)
74. Gupta PC. A study of dose-response relationship between tobacco habits and oral leukoplakia. Br J Cancer 1984;50:527-31. (Pubitemid 14015595)
75. Lee CH, Ko YC, Huang HL, et al. The precancer risk of betel quid chewing, tobacco use and alcohol consumption in oral leukoplakia and oral submucous fibrosis in southern Taiwan. Br J Cancer 2003;88:366-72.
76. Yen AM, Chen SC, Chen TH. Dose-response relationships of oral habits associated with the risk of oral pre-malignant lesions among men who chew betel quid. Oral Oncol 2007;43: 634-8. (Pubitemid 47058364)
77. Thomas G, Hashibe M, Jacob BJ, et al. Risk factors for multiple oral premalignant lesions. Int J Cancer 2003;107:285-91. (Pubitemid 37152912)
78. Yen AM, Chen SC, Chang SH, et al. The effect of betel quid and cigarette on multistate progression of oral pre-malignancy. J Oral Pathol Med 2008;37:417-22.
79. Thomas SJ, Harris R, Ness AR, et al. Betel quid not containing tobacco and oral leukoplakia: a report on a cross-sectional study in Papua New Guinea and a meta-analysis of current evidence. Int J Cancer 2008;123:1871-6.
80. Peacock Jr EE, Greenberg BG, Brawley BW. The effect of snuff and tobacco on the production of oral carcinoma: an experimental and epidemiological study. Ann Surg 1960;151:542-50.
81. Andersson G, Axéll T, Larsson A. Clinical classification of Swedish snuff dippers' lesions supported by histology. J Oral Pathol Med 1991;20:253-7.
82. Sinusas K, Coroso JG. A 10-yr study of smokeless tobacco use in a professional baseball organization. Med Sci Sports Exerc 2006;38:1204-7. (Pubitemid 44036689)
83. Fisher MA, Bouquot JE, Shelton BJ. Assessment of risk factors for oral leukoplakia in West Virginia. Community Dent Oral Epidemiol 2005;33:45-52. (Pubitemid 41638658)
84. Wolfe MD, Carlos JP. Oral health effects of smokeless tobacco use in Navajo Indian adolescents. Community Dent Oral Epidemiol 1987;15:230-5.
85. Tomar SL, Winn DM, Swango PA, et al. Oral mucosal smokeless tobacco lesions among adolescents in the United States. J Dent Res 1997;76:1277-86. (Pubitemid 127732688)
86. Giunta JL, Connolly G. The reversibility of leukoplakia caused by smokeless tobacco. J Am Dent Assoc 1986;113:50-2.
87. Larsson A, Axéll T, Andersson G. Reversibility of snuff dippers' lesion in Swedish moist snuff users: a clinical and histologic follow-up study. J Oral Pathol Med 1991;20:258-64.
88. Martin GC, Brown JP, Eifler CW, et al. Oral leukoplakia status six weeks after cessation of smokeless tobacco use. J Am Dent Assoc 1999;130:945-54.
89. Pindborg JJ, Sirsat SM. Oral submucous fibrosis. Oral Surg Oral Med Oral Pathol 1966;22:764-79.
90. Maher R, Lee AJ, Warnakulasuriya KA, et al. Role of areca nut in the causation of oral submucous fibrosis: a case-control study in Pakistan. J Oral Pathol Med 1994;23:65-9.
91. Sinor PN, Gupta PC, Murti PR, et al. A case-control study of oral submucous fibrosis with special reference to the etiologic role of areca nut. J Oral Pathol Med 1990;19:94-8. (Pubitemid 20227744)
92. Lee JJ, Kuo MY, Cheng SJ, et al. Higher expressions of p53 and proliferating cell nuclear antigen (PCNA) in atrophic oral lichen planus and patients with areca quid chewing. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;99:471-8.
93. Zain RB, Ikeda N, Gupta PC, et al. Oral mucosal lesions associated with betel quid, areca nut and tobacco chewing habits: consensus from a workshop held in Kuala Lumpur, Malaysia, November 25-27, 1996. J Oral Pathol Med 1999;28:1-4. (Pubitemid 28564735)
94. Wynder EL, Bross IJ. Aetiological factors in mouth cancer; an approach to its prevention. Br Med J 1957;1:1137-43.
95. McDowell JD. An overview of epidemiology and common risk factors for oral squamous cell carcinoma. Otolaryngol Clin North Am 2006;39:277-94.
96. Chakrabarti RN, Dutta K, Sikdar S, et al. Smokeless tobacco and premalignant and malignant lesions of the oral cavity. Indian J Med Sci 1991;45:273-5.
97. Lin YS, Jen YM, Wang BB, et al. Epidemiology of oral cavity cancer in taiwan with emphasis on the role of betel nut chewing. ORL J Otorhinolaryngol Relat Spec 2005;67:230-6.
98. Dikshit RP, Kanhere S. Tobacco habits and risk of lung, oropharyngeal and oral cavity cancer: a population-based case-control study in Bhopal, India. Int J Epidemiol 2000;29:609-14. (Pubitemid 30612225)
99. Sankaranarayanan R, Duffy SW, Padmakumary G, et al. Tobacco chewing, alcohol and nasal snuff in cancer of the gingiva in Kerala, India. Br J Cancer 1989;60:638-43. (Pubitemid 19251467)
100. Blot WJ, McLaughlin JK, Winn DM, et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res 1988;48:3282-7.
101. Boffetta P, Hecht S, Gray N, et al. Smokeless tobacco and cancer. Lancet Oncol 2008;9:667-75. (Pubitemid 351878052)
102. Lewin F, Norell SE, Johansson H, et al. Smoking tobacco, oral snuff, and alcohol in the etiology of squamous cell carcinoma of the head and neck: a population-based case-referent study in Sweden. Cancer 1998;82:1367-75. (Pubitemid 28155400)
103. Schildt EB, Eriksson M, Hardell L, et al. Oral snuff, smoking habits and alcohol consumption in relation to oral cancer in a Swedish case-control study. Int J Cancer 1998;77:341-6. (Pubitemid 28299867)
104. Rodu B, Cole P. Smokeless tobacco use and cancer of the upper respiratory tract. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002;93:511-5. (Pubitemid 41124637)
105. Roosaar A, Johansson AL, Sandborgh-Englund G, et al. A long-term follow-up study on the natural course of snusinduced lesions among Swedish snus users. Int J Cancer 2006;119:392-7.
106. Luo J, Ye W, Zendehdel K, et al. Oral use of Swedish moist snuff (snus) and risk for cancer of the mouth, lung, and pancreas in male construction workers: a retrospective cohort study. Lancet 2007;369:2015-20. (Pubitemid 46899161)
107. Boffetta P, Aagnes B, Weiderpass E, et al. Smokeless tobacco use and risk of cancer of the pancreas and other organs. Int J Cancer 2005;114:992-5.
108. Rosenquist K, Wennerberg J, Schildt EB, et al. Use of Swedish moist snuff, smoking and alcohol consumption in the aetiology of oral and oropharyngeal squamous cell carcinoma. A population-based case-control study in southern Sweden. Acta Otolaryngol 2005;125:991-8. (Pubitemid 41306312)
109. Roosaar A, Johansson AL, Sandborgh-Englund G, et al. Cancer and mortality among users and nonusers of snus. Int J Cancer 2008;123:168-73. (Pubitemid 351705205)
110. Sapkota A, Gajalakshmi V, Jetly DH, et al. Smokeless tobacco and increased risk of hypopharyngeal and laryngeal cancers: a multicentric case-control study from India. Int J Cancer 2007;121:1793-8. (Pubitemid 47417299)
111. Lagergren J, Bergström R, Lindgren A, et al. The role of tobacco, snuff and alcohol use in the aetiology of cancer of the oesophagus and gastric cardia. Int J Cancer 2000;85:340-6. (Pubitemid 30030406)
112. Zendehdel K, Nyrén O, Luo J, et al. Risk of gastroesophageal cancer among smokers and users of Scandinavian moist snuff. Int J Cancer 2008;122:1095-9. (Pubitemid 351214008)
113. Ye W, Ekström AM, Hansson LE, et al. Tobacco, alcohol and the risk of gastric cancer by sub-site and histologic type. Int J Cancer 1999;83:223-9. (Pubitemid 29449101)
114. Chao A, Thun MJ, Henley SJ, et al. Cigarette smoking, use of other tobacco products and stomach cancer mortality in US adults: The Cancer Prevention Study II. Int J Cancer 2002;101:380-9. (Pubitemid 34987526)
115. Muscat JE, Stellman SD, Hoffmann D, et al. Smoking and pancreatic cancer in men and women. Cancer Epidemiol Biomarkers Prev 1997;6:15-9. (Pubitemid 27030422)
116. Alguacil J, Silverman DT. Smokeless and other noncigarette tobacco use and pancreatic cancer: a case-control study based on direct interviews. Cancer Epidemiol Biomarkers Prev 2004;13:55-8. (Pubitemid 38116621)
117. Hassan MM, Abbruzzese JL, Bondy ML, et al. Passive smoking and the use of noncigarette tobacco products in association with risk for pancreatic cancer: a case-control study. Cancer 2007;109:2547-56. (Pubitemid 46906475)
118. Nordenvall C, Nilsson PJ, Ye W, et al. Smoking, snus use and risk of right-and left-sided colon, rectal, and anal cancer, a 37-year follow-up study. Int J Cancer 2011;128:157-65.
119. Bolinder G, Alfredsson L, Englund A, et al. Smokeless tobacco use and increased cardiovascular mortality among Swedish construction workers. Am J Public Health 1994;84: 399-404. (Pubitemid 24107823)
120. Rafique M. Clinico-pathological features of bladder carcinoma in women in Pakistan and smokeless tobacco as a possible risk factor. World J Surg Oncol 2005;3:53.
121. Slattery ML, Schumacher MC, West DW, et al. Smoking and bladder cancer. The modifying effect of cigarettes on other factors. Cancer 1988;61:402-8. (Pubitemid 18056502)
122. Hsing AW, McLaughlin JK, Schuman LM, et al. Diet, tobacco use, and fatal prostate cancer: results from the Lutheran Brotherhood Cohort Study. Cancer Res 1990;50:6836-40. (Pubitemid 20361078)
123. Spangler JG, Michielutte R, Bell RA, et al. Association between smokeless tobacco use and breast cancer among Native-American women in North Carolina. Ethn Dis 2001;11:36-43. (Pubitemid 33584108)
124. Rahman MA, Zaman MM. Smoking and smokeless tobacco consumption: possible risk factors for coronary heart disease among young patients attending a tertiary care cardiac hospital in Bangladesh. Public Health 2008;122:1331-8.
125. Huhtasaari F, Asplund K, Lundberg V, et al. Tobacco and myocardial infarction: is snuff less dangerous than cigarettes? BMJ 1992;305:1252-6.
126. Huhtasaari F, Lundberg V, Eliasson M, et al. Smokeless tobacco as a possible risk factor for myocardial infarction: a population-based study in middle-aged men. J AmColl Cardiol 1999;34:1784-90.
127. Johansson SE, Sundquist K, Qvist J, et al. Smokeless tobacco and coronary heart disease: a 12-year follow-up study. Eur J Cardiovasc Prev Rehabil 2005;12:387-92. (Pubitemid 41192172)
128. Hergens MP, Ahlbom A, Andersson T, et al. Swedish moist snuff and myocardial infarction among men. Epidemiology 2005;16:12-6. (Pubitemid 40239273)
129. Hergens MP, Alfredsson L, Bolinder G, et al. Long-term use of Swedish moist snuff and the risk of myocardial infarction amongst men. J Intern Med 2007;262:351-9. (Pubitemid 47246970)
130. Wennberg P, Eliasson M, Hallmans G, et al. The risk of myocardial infarction and sudden cardiac death amongst snuff users with or without a previous history of smoking. J Intern Med 2007;262:360-7. (Pubitemid 47246968)
131. Boffetta P, Straif K. Use of smokeless tobacco and risk of myocardial infarction and stroke: systematic review with meta-analysis. BMJ 2009;339:b3060, doi:10.1136/bmj.b3060.
132. Janzon E, Hedblad B. Swedish snuff and incidence of cardiovascular disease A population-based cohort study. BMC Cardiovasc Disord 2009;9:21.
133. Asplund K, Nasic S, Janlert U, et al. Smokeless tobacco as a possible risk factor for stroke in men: a nested case-control study. Stroke 2003;34:1754-9. (Pubitemid 36842641)
134. Hergens MP, Lambe M, Pershagen G, et al. Smokeless tobacco and the risk of stroke. Epidemiology 2008;19:794-9.
135. Haglund B, Eliasson M, Stenbeck M, et al. Is moist snuff use associated with excess risk of IHD or stroke? A longitudinal follow-up of snuff users in Sweden. Scand J Public Health 2007;35:618-22. (Pubitemid 350176909)
136. McPhaul M, Punzi HA, Sandy A, et al. Snuff-induced hypertension in pheochromocytoma. JAMA 1984;252:2860-2. (Pubitemid 15219396)
137. Westman EC. Does smokeless tobacco cause hypertension? South Med J 1995;88:716-20.
138. Bolinder GM, Ahlborg BO, Lindell JH. Use of smokeless tobacco: blood pressure elevation and other health hazards found in a large-scale population survey. J Intern Med 1992;232:327-34.
139. Bolinder G, de Faire U. Ambulatory 24-h blood pressure monitoring in healthy, middle-aged smokeless tobacco users, smokers, and non tobacco users. Am J Hypertens 1998;11:1153-63.
140. Sogut O, Sayhan MB, Ustundag M, et al. Paroxysmal atrial fibrillation after smokeless tobacco (Maras powder) use. J Chin Med Assoc 2009;72:265-7.
141. Wallenfeldt K, Hulthe J, Bokemark L, et al. Carotid and femoral atherosclerosis, cardiovascular risk factors and C-reactive protein in relation to smokeless tobacco use or smoking in 58-year-old men. J Intern Med 2001;250:492-501. (Pubitemid 34008759)
142. Gupta BK, Kaushik A, Panwar RB, et al. Cardiovascular risk factors in tobacco-chewers: a controlled study. J Assoc Physicians India 2007;55:27-31.
143. Tucker LA. Use of smokeless tobacco, cigarette smoking, and hypercholesterolemia. Am J Public Health 1989;79:1048-50. (Pubitemid 19207446)
144. Persson PG, Carlsson S, Svanström L, et al. Cigarette smoking, oral moist snuff use and glucose intolerance. J Intern Med 2000;248:103-10. (Pubitemid 30603031)
145. Eliasson M, Lundblad D, Hägg E. Cardiovascular risk factors in young snuff-users and cigarette smokers. J Intern Med 1991;230:17-22.
146. Eliasson M, Asplund K, Evrin PE, et al. Relationship of cigarette smoking and snuff dipping to plasma fibrinogen, fibrinolytic variables and serum insulin. The Northern Sweden MONICA Study. Atherosclerosis 1995;113:41-53.
147. Subramoney S, Gupta PC. Anemia in pregnant women who use smokeless tobacco. Nicotine Tob Res 2008;10:917-20. (Pubitemid 351974073)
148. Wikström AK, Stephansson O, Cnattingius S. Tobacco use during pregnancy and preeclampsia risk: effects of cigarette smoking and snuff. Hypertension 2010;55:1254-9.
149. England LJ, Levine RJ, Mills JL, et al. Adverse pregnancy outcomes in snuff users. Am J Obstet Gynecol 2003;189:939-43. (Pubitemid 37373873)
150. Gupta PC, Subramoney S. Smokeless tobacco use and risk of stillbirth: a cohort study in Mumbai, India. Epidemiology 2006;17:47-51.
151. Steyn K, de Wet T, Saloojee Y, et al. The influence of maternal cigarette smoking, snuff use and passive smoking on pregnancy outcomes: the Birth To Ten Study. Paediatr Perinat Epidemiol 2006;20:90-9.
152. Pershagen G. Smokeless tobacco. Br Med Bull 1996;52:50-7. (Pubitemid 26039048)
153. Persson PG, Hellers G, Ahlbom A. Use of oral moist snuff and inflammatory bowel disease. Int J Epidemiol 1993;22:1101-3. (Pubitemid 24025688)
154. O'Reilly EJ, McCullough ML, Chao A, et al. Smokeless tobacco use and the risk of Parkinson's disease mortality. Mov Disord 2005;20:1383-4. (Pubitemid 41645921)
155. Chinachoti N, Tangchai P. Pulmonary alveolar microlithiasis associated with the inhalation of snuff in Thailand. Dis Chest 1957;32:687-9.
156. Thomas T, Thomas E, Prusty S, et al. Snuff granuloma of the lung. Report of a case. Dis Chest 1964;46:613-6.
157. Hoppichler F, Lechleitner M, König P, et al. Snuff and recurring pulmonary infiltrations in chronic renal failure. Lancet 1992;339:500-1.
158. Ayo-Yusuf OA, Reddy PS, van den Borne BW. Association of snuff use with chronic bronchitis among South African women: implications for tobacco harm reduction. Tob Control 2008;17:99-104.
159. Maduka SO, Osim EE, Nneli RO, et al. Effect of occupational exposure to local powdered tobacco (snuff) on pulmonary function in south eastern Nigerians. Niger J Physiol Sci 2009;24.
160. Sinusas K, Coroso JG. Smokeless tobacco cessation: report of a preliminary trial using nicotine chewing gum. J Fam Pract 1993;37:264-7. (Pubitemid 23269169)
161. Hatsukami D, Jensen J, Allen S, et al. Effects of behavioral and pharmacological treatment on smokeless tobacco users. J Consult Clin Psychol 1996;64:153-61. (Pubitemid 26076077)
162. Ebbert JO, Dale LC, Severson H, et al. Nicotine lozenges for the treatment of smokeless tobacco use. Nicotine Tob Res 2007;9:233-40. (Pubitemid 47009069)
163. Ebbert JO, Severson HH, Croghan IT, et al. A randomized clinical trial of nicotine lozenge for smokeless tobacco use. Nicotine Tob Res 2009;11:1415-23.
164. Ebbert JO, Dale LC, Patten CA, et al. Effect of high-dose nicotine patch therapy on tobacco withdrawal symptoms among smokeless tobacco users. Nicotine Tob Res 2007;9:43-52. (Pubitemid 47009043)
165. Dale LC, Ebbert JO, Glover ED, et al. for the treatment of smokeless tobacco use. Drug Alcohol Depend 2007;90:56-63.
166. Aggarwal A, Jain M, Jiloha RC. Varenicline for smokeless tobacco dependence. J Postgrad Med 2010;56:50.
167. Hatsukami DK, Boyle RG. Prevention and treatment of smokeless tobacco use. Adv Dent Res 1997;11:342-9.
168. Ebbert JO, Edmonds A, Luo X, et al. Smokeless tobacco reduction with the nicotine lozenge and behavioral intervention. Nicotine Tob Res 2010;12:823-7.
169. Ebbert JO, Montori V, Vickers KS, et al. Interventions for smokeless tobacco use cessation. Cochrane Database Syst Rev 2007;(4):CD004306.
170. Ebbert JO, Dale LC, Vickers KS, et al. Residential treatment for smokeless tobacco use: a case series. J Subst Abuse Treat 2004;26:261-7. (Pubitemid 38759142)
171. Ebbert JO, Croghan IT, North F, et al. A pilot study to assess smokeless tobacco use reduction with varenicline. Nicotine Tob Res 2010;12:1037-40.
172. Perriot J. L'aide à l'arrêt du tabagisme des fumeurs irréductibles. Courrier Addiction 2010;1:15-7.
173. Lemarié E. La pneumologie fondée sur les preuves. Paris: Éditions Margaux Orange; 2008.
174. Perriot J. La conduite de l'aide au sevrage tabagique. Rev Mal Respir 2006;23:3S85-105S.
175. Costa ML, Cohen JE, Chaiton MO, et al. Hardcore definitions and their application to a population-based sample of smokers. Nicotine Tob Res 2010;12:860-4.
176. Emery S, Gilpin EA, Ake C, et al. Characterizing and identifying "hard-core" smokers: implications for further reducing smoking prevalence. Am J Public Health 2000;90: 387-94. (Pubitemid 30115413)
177. Augustson E, Marcus S. Use of the current population survey to characterize subpopulations of continued smokers: a national perspective on the "hardcore" smoker phenomenon. Nicotine Tob Res 2004;6:621-9. (Pubitemid 39248148)
178. Thompson LE, Barnett JR, Pearce JR. Scared straight? Fear appeal antismoking campaigns, risk, self-efficacy and addiction. Health Risk Soc 2009;11:181-6.
179. Lund KE, Mc Neill A, Scheffels J. The use of snus for quitting smoking compared with medicinal products. Nicotine Tob Res 2010;12:817-22.
180. Zhu SH, Wang JB, Hartman A, et al. Quitting cigarettes completely or switching to smokeless tobacco: do US data replicate the Swedish results? Tob Control 2009;18: 82-7.
181. Galanti MR, Rosendahl I, Wickholm S. The development of tobacco use in adolescence among "snus starters" and "cigarette starters": an analysis of the Swedish "BROMS" cohort. Nicotine Tob Res 2008;10:315-23. (Pubitemid 351201315)
182. Connaissances actuelles des effets pour la santé du tabac oral avec attention particulière au snus suédois. Rapport de la Société française de tabacologie pour la Direction Générale de la Santé. 1er février 2008.